Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 12/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18797720 | 0.84 | RORC (0.47) | PDK2RORCHDAC4 | |
| SCHEMBL18797718 | 0.82 | RORC (0.42) | PDK2CA12CA1CA2CA7 | |
| SCHEMBL18797729 | 0.79 | PDK2 (0.38) | PDK2CA12CA1CA2CA7 | |
| SCHEMBL18797728 | 0.79 | RORC (0.42) | PDK2CA12CA1CA2CA7 | |
| SCHEMBL28234906 | 0.78 | PDK2 (0.55) | PDK2CA1CA2CA9 | |
| SCHEMBL18821039 | 0.76 | RORC (0.42) | PDK2RORCHDAC4 | |
| SCHEMBL403705 | 0.74 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30829295 | 0.73 | L3MBTL1 (0.48) | PDK2RORC | |
| SCHEMBL28100618 | 0.72 | PDK2 (0.43) | PDK2RORCHDAC4 | |
| SCHEMBL21127546 | 0.72 | CA12 (0.44) | PDK2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368535-B1 | HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORGAMMAT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3368535-B1 | HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORGAMMAT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10584121-B2 | Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190194186-A1 | HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2019-06-27 | — | — | US | disclosed |
| EP-3368535-A1 | HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORGAMMAT INHIBITORS AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017075185-A1 | HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORGAMMAT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075185-A1 | HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORGAMMAT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194186-A1 | HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORA, RORC | PDK2 1463/4885CA12 1722/4885CA1 1648/4885 |
| US-10584121-B2 | Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof | RORB, RORA, RORC | PDK2 1463/4885CA12 1722/4885CA1 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.